Overview

Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease

Status:
Terminated

Trial end date:
2019-05-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the maximum tolerated dose, dose limiting side effects, and the safety of increasing doses of lenalidomide in patients with AML and MDS who have a small amount of detectable disease after allogeneic stem cell transplant.

Phase:

Phase 1

Details

Lead Sponsor:

University of Florida

Collaborator:

Celgene Corporation

Treatments:

Lenalidomide
Thalidomide